Jason Alexander Efstathiou

Jason Alexander Efstathiou

Auto-generated profile, based on publicly available information

Jason Alexander Efstathiou

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in European Urology
Verified
Journal Article
Closed access
MCMaryBeth B. Culp
MaryBeth B. Culp
ISIsabelle Soerjomataram
Isabelle Soerjomataram
JEJason A. Efstathiou
Jason A. Efstathiou
FBFreddie Bray
Freddie Bray
AJAhmedin Jemal
Ahmedin Jemal

26 October 2023 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
LDLars Dyrskjøt
Lars Dyrskjøt
DHDonna E. Hansel
Donna E. Hansel
JEJason A. Efstathiou
Jason A. Efstathiou
MKMargaret A. Knowles
Margaret A. Knowles
MGMatthew D. Galsky
Matthew D. Galsky
DTDan Theodorescu
Dan Theodorescu

1 April 2012 in European Urology
Verified
Journal Article
Closed access
JEJason A. Efstathiou
Jason A. Efstathiou
DSDaphna Y. Spiegel
Daphna Y. Spiegel
WSWilliam U. Shipley
William U. Shipley
NHNiall M. Heney
Niall M. Heney
DKDonald S. Kaufman
Donald S. Kaufman
AZAnthony L. Zietman
Anthony L. Zietman

1 June 2017 in European Urology
Verified
Journal Article
Closed access
NGNicholas J. Giacalone
Nicholas J. Giacalone
WSWilliam U. Shipley
William U. Shipley
RCRebecca H. Clayman
Rebecca H. Clayman
ANAndrzej Niemierko
Andrzej Niemierko
MDMichael Drumm
Michael Drumm
JEJason A. Efstathiou
Jason A. Efstathiou

1 September 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JEJason A. Efstathiou
Jason A. Efstathiou
KBKyounghwa Bae
Kyounghwa Bae
WSWilliam U. Shipley
William U. Shipley
DKDonald S. Kaufman
Donald S. Kaufman
MHMichael P. Hagan
Michael P. Hagan
HSHoward M. Sandler
Howard M. Sandler
Purpose: In selected patients with muscle-invasive bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy) with salvage cystectomy, if necessary, can achieve survival rates similar to radical cystectomy. We investigated late pelvic toxicity after chemoradiotherapy for patients treated on prospective protocols. Patients and Methods: Between 1990 and 2002, 285 eligible patients enrolled on four prospective protocols (Radiation Therapy Oncology Group [RTOG] 8903, 9506, 9706, 9906) and 157 underwent combined-modality therapy, surviving ≥ 2 years from start of treatment with their bladder intact. Rates of late genitourinary (GU) and GI toxicity were assessed using the RTOG Late Radiation Morbidity Schema, with worst toxicity grade (scale 0 to 5) occurring ≥ 180 days after start of consolidation therapy reported for each patient. Persistence of toxicity was defined as grade 3+ toxicity not decreasing by at least one grade. Logistic and Cox regression analyses were performed to evaluate relationship between clinical characteristics, frequency, and time to late grade 3+ pelvic toxicity. Covariates included age, sex, stage, presence of carcinoma in situ, completeness of TURBT, and protocol. Results: Median follow-up was 5.4 years (range, 2.0 to 13.2 years). Seven percent of patients experienced late grade 3+ pelvic toxicity: 5.7% GU and 1.9% GI. In only one of nine patients did a grade 3+ GU toxicity persist. Notably there were no late grade 4 toxicities and no treatment-related deaths. None of the clinical variables studied predicted for late grade 3+ pelvic toxicity. Conclusion: Rates of significant late pelvic toxicity for patients completing combined-modality therapy for invasive bladder cancer and retaining their native bladder are low.

1 October 2008 in European Urology
Verified
Journal Article
Closed access
JEJason A. Efstathiou
Jason A. Efstathiou
KBKyounghwa Bae
Kyounghwa Bae
WSWilliam U. Shipley
William U. Shipley
GHGerald E. Hanks
Gerald E. Hanks
MPMiljenko V. Pilepich
Miljenko V. Pilepich
MSMatthew R. Smith
Matthew R. Smith